原创性新药候选物转让项目.PDFVIP

英国国家医学研究院科技部 MRC Technology . Partnering opportunities 原创性新药候选物转让项目 Humanised Bispecific Antibody for Oncology indications Epidermal growth factor receptor (EGFR) is an attractive target for cancer therapeutics with two FDA approved mAbs (cetuximab nad panitumumab) on the market. Although EGFR is overexpressed to various degrees on cancer cells, EGFR antibodies also target EGFR on normal tissues which can cause dose-limiting side effects. Therefore, EGFR antibodies recognising tumour-specific EGFR epitopes, such as the common EGFR variant III (EGFRvIII), offer the potential to enhance therapeutic specificity. In addition, bispecific antibodies incorporating a CD3 T cell recruitment arm also offer the potential for greater therapeutic efficacy. We have a humanized bispecific antibody that specifically binds to EGFRvIII and CD3 and demonstrates strong efficacy in xenograft glioma models. 用于肿瘤适应症的人源化双功能抗体 在市场上有两个FDA批准的抗体（西妥昔单抗和帕尼单抗）的情况下，表皮生长因子受体（EGFR ）是 一个吸引人的癌症治疗靶标。虽然EGFR在癌细胞上有不同程度的过度表达，但EGFR抗体也靶向 正常组织上的EGFR ，因此可造成剂量限制性副作用。新型的EGFR抗体辨认肿瘤特异性EGFR表位， EGFR变异体 III （EGFRvIII ），为提高治疗特异性提供了潜能。此外，融入CD3 T细胞募 集作用的双特异性抗体也为提高治疗效力提供了潜能。我们现在拥有一种人源化双功能抗体，可特异 性结合EGFRvIII 和CD3 ，并在异种移植神经胶质瘤模型中显示强大的效力。 Kinase Inhibitor for Neurodegenerative Diseases. Microtubule-Affinity-Regulating-Kinase (MARK) is a protein kinase which phosphorylates of tau-protein. Hyper-phosphorylated tau protein results in the formation of neurofibrillary tangles (NFTs), which are one of the hallmarks of Alzheimer’s disease pathology and responsible for the neurodegeneration. We have developed a series of highly potent small mo